Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Court Hands Novartis Setback In Gleevec Patent Case

This article was originally published in PharmAsia News

Executive Summary

Novartis suffered a major blow Aug. 6 when an Indian court dismissed its challenge of a key government provision that blocks the company from obtaining a patent for its oncologic Gleevec (imatinib)

You may also be interested in...



IP Protection Concerns Grow In India, PhRMA Says

Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America

IP Protection Concerns Grow In India, PhRMA Says

Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America

Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System

Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.

UsernamePublicRestriction

Register

SC066494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel